Search
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigational[A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONProducts: ACETILCISTEINA EGHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).
Taurine
go.drugbank.com/drugs/DB01956ApprovedInvestigationalNutraceutical[L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]
Mixtures: SMOFKABIVEN EF, Numeta G 13 % E Emulsion zur InfusionTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … to be approved by the FDA.
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigational[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Gefurulimab
go.drugbank.com/drugs/DB18928InvestigationalGefurulimab is under investigation in clinical trial NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis).